Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma

Loading news article.

Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma | WAPE

Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma

Article summary

Related companies

Comments —